Literature DB >> 29238965

Sieve analysis using the number of infecting pathogens.

Dean Follmann1, Chiung-Yu Huang2.   

Abstract

Assessment of vaccine efficacy as a function of the similarity of the infecting pathogen to the vaccine is an important scientific goal. Characterization of pathogen strains for which vaccine efficacy is low can increase understanding of the vaccine's mechanism of action and offer targets for vaccine improvement. Traditional sieve analysis estimates differential vaccine efficacy using a single identifiable pathogen for each subject. The similarity between this single entity and the vaccine immunogen is quantified, for example, by exact match or number of mismatched amino acids. With new technology, we can now obtain the actual count of genetically distinct pathogens that infect an individual. Let F be the number of distinct features of a species of pathogen. We assume a log-linear model for the expected number of infecting pathogens with feature "f," <mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mi>f</mml:mi> <mml:mo>=</mml:mo> <mml:mn>1</mml:mn> <mml:mo>,</mml:mo> <mml:mo>…</mml:mo> <mml:mo>,</mml:mo> <mml:mi>F</mml:mi></mml:math> . The model can be used directly in studies with passive surveillance of infections where the count of each type of pathogen is recorded at the end of some interval, or active surveillance where the time of infection is known. For active surveillance, we additionally assume that a proportional intensity model applies to the time of potentially infectious exposures and derive product and weighted estimating equation (WEE) estimators for the regression parameters in the log-linear model. The WEE estimator explicitly allows for waning vaccine efficacy and time-varying distributions of pathogens. We give conditions where sieve parameters have a per-exposure interpretation under passive surveillance. We evaluate the methods by simulation and analyze a phase III trial of a malaria vaccine. Published 2017. This article is a U.S. Government work and is in the public domain in the USA.

Entities:  

Keywords:  Competing risks; Cox regression; Empirical process; Infectious disease; Marked process; Multiple Outputation; Within Cluster Resampling

Mesh:

Substances:

Year:  2017        PMID: 29238965      PMCID: PMC6004265          DOI: 10.1111/biom.12833

Source DB:  PubMed          Journal:  Biometrics        ISSN: 0006-341X            Impact factor:   2.571


  16 in total

1.  Multiple outputation: inference for complex clustered data by averaging analyses from independent data.

Authors:  Dean Follmann; Michael Proschan; Eric Leifer
Journal:  Biometrics       Date:  2003-06       Impact factor: 2.571

2.  Longitudinal data analysis for discrete and continuous outcomes.

Authors:  S L Zeger; K Y Liang
Journal:  Biometrics       Date:  1986-03       Impact factor: 2.571

Review 3.  Clinical development of RTS,S/AS malaria vaccine: a systematic review of clinical Phase I-III trials.

Authors:  Selidji T Agnandji; José F Fernandes; Emmanuel B Bache; Michael Ramharter
Journal:  Future Microbiol       Date:  2015-10-06       Impact factor: 3.165

4.  Applying Cox regression to competing risks.

Authors:  M Lunn; D McNeil
Journal:  Biometrics       Date:  1995-06       Impact factor: 2.571

5.  Comparison of competing risks failure time methods and time-independent methods for assessing strain variations in vaccine protection.

Authors:  P B Gilbert
Journal:  Stat Med       Date:  2000-11-30       Impact factor: 2.373

6.  Mark-specific proportional hazards model with multivariate continuous marks and its application to HIV vaccine efficacy trials.

Authors:  Yanqing Sun; Mei Li; Peter B Gilbert
Journal:  Biostatistics       Date:  2012-07-03       Impact factor: 5.899

7.  Incorporating founder virus information in vaccine field trials.

Authors:  Dean Follmann; Chiung-Yu Huang
Journal:  Biometrics       Date:  2015-03-13       Impact factor: 2.571

8.  Mark-specific hazard ratio model with multivariate continuous marks: an application to vaccine efficacy.

Authors:  M Juraska; P B Gilbert
Journal:  Biometrics       Date:  2013-02-19       Impact factor: 2.571

9.  Statistical methods for assessing differential vaccine protection against human immunodeficiency virus types.

Authors:  P B Gilbert; S G Self; M A Ashby
Journal:  Biometrics       Date:  1998-09       Impact factor: 2.571

10.  A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants.

Authors:  Selidji Todagbe Agnandji; Bertrand Lell; José Francisco Fernandes; Béatrice Peggy Abossolo; Barbara Gaelle Nfono Ondo Methogo; Anita Lumeka Kabwende; Ayola Akim Adegnika; Benjamin Mordmüller; Saadou Issifou; Peter Gottfried Kremsner; Jahit Sacarlal; Pedro Aide; Miguel Lanaspa; John J Aponte; Sonia Machevo; Sozinho Acacio; Helder Bulo; Betuel Sigauque; Eusébio Macete; Pedro Alonso; Salim Abdulla; Nahya Salim; Rose Minja; Maxmillian Mpina; Saumu Ahmed; Ali Mohammed Ali; Ali Takadir Mtoro; Ali Said Hamad; Paul Mutani; Marcel Tanner; Halidou Tinto; Umberto D'Alessandro; Hermann Sorgho; Innocent Valea; Biébo Bihoun; Issa Guiraud; Berenger Kaboré; Olivier Sombié; Robert Tinga Guiguemdé; Jean Bosco Ouédraogo; Mary J Hamel; Simon Kariuki; Martina Oneko; Chris Odero; Kephas Otieno; Norbert Awino; Meredith McMorrow; Vincent Muturi-Kioi; Kayla F Laserson; Laurence Slutsker; Walter Otieno; Lucas Otieno; Nekoye Otsyula; Stacey Gondi; Allan Otieno; Victorine Owira; Esther Oguk; George Odongo; Jon Ben Woods; Bernhards Ogutu; Patricia Njuguna; Roma Chilengi; Pauline Akoo; Christine Kerubo; Charity Maingi; Trudie Lang; Ally Olotu; Philip Bejon; Kevin Marsh; Gabriel Mwambingu; Seth Owusu-Agyei; Kwaku Poku Asante; Kingsley Osei-Kwakye; Owusu Boahen; David Dosoo; Isaac Asante; George Adjei; Evans Kwara; Daniel Chandramohan; Brian Greenwood; John Lusingu; Samwel Gesase; Anangisye Malabeja; Omari Abdul; Coline Mahende; Edwin Liheluka; Lincoln Malle; Martha Lemnge; Thor G Theander; Chris Drakeley; Daniel Ansong; Tsiri Agbenyega; Samuel Adjei; Harry Owusu Boateng; Theresa Rettig; John Bawa; Justice Sylverken; David Sambian; Anima Sarfo; Alex Agyekum; Francis Martinson; Irving Hoffman; Tisungane Mvalo; Portia Kamthunzi; Rutendo Nkomo; Tapiwa Tembo; Gerald Tegha; Mercy Tsidya; Jane Kilembe; Chimwemwe Chawinga; W Ripley Ballou; Joe Cohen; Yolanda Guerra; Erik Jongert; Didier Lapierre; Amanda Leach; Marc Lievens; Opokua Ofori-Anyinam; Aurélie Olivier; Johan Vekemans; Terrell Carter; David Kaslow; Didier Leboulleux; Christian Loucq; Afiya Radford; Barbara Savarese; David Schellenberg; Marla Sillman; Preeti Vansadia
Journal:  N Engl J Med       Date:  2012-11-09       Impact factor: 91.245

View more
  1 in total

Review 1.  Impacts of Ecology, Parasite Antigenic Variation, and Human Genetics on RTS,S/AS01e Malaria Vaccine Efficacy.

Authors:  Griffin J Bell; Selidji Todagbe Agnandji; Kwaku Poku Asante; Anita Ghansah; Portia Kamthunzi; Michael Emch; Jeffrey A Bailey
Journal:  Curr Epidemiol Rep       Date:  2021-07-30
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.